|Bid||1.9900 x 1000|
|Ask||2.3000 x 800|
|Day's Range||2.0400 - 2.1700|
|52 Week Range||1.1300 - 4.0400|
|Beta (5Y Monthly)||0.83|
|PE Ratio (TTM)||7.11|
|Earnings Date||Nov 02, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Orgenesis ( NASDAQ:ORGS ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.99m (down 7.9% from 3Q 2021...
Orgenesis Inc. ( NASDAQ:ORGS ) is possibly approaching a major achievement in its business, so we would like to shine...
Secures up to $50 Million of Funding from Metalmark Capital Partners Expected to Accelerate Rollout of Point-of-Care Services Reduces operating expenses by 49% to achieve nearly breakeven income from operation for the third quarter of 2022 Orgenesis to Host Conference Call on Friday, November 11, 2022 at 8:00 AM Eastern Time GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potentia